Daphne Chun-Che Chien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daphne Chun-Che Chien has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Nathachit Limjunyawong
Center of Research Excellence in Allergy & Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
2 shared publications - Xinzhong Dong
Solomon H. Snyder Department of Neuroscience, Howard Hughes Medical Institute, Johns Hopkins School of Medicine
2 shared publications - Akira Sawa
Johns Hopkins University
1 shared publication - Alena V. Savonenko
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
1 shared publication - Brendan P. Lucey
Washington University School of Medicine
1 shared publication - Bryan L. Roth
Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, USA
1 shared publication
Latest Publications
- 8 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (746) , eadk8198
MRGPRX4 mediates phospho-drug–associated pruritus in a humanized mouse model
The phosphate modification of drugs is a common chemical strategy to increase solubility and allow for parenteral administration. Unfortunately, phosphate modifications often elicit treatment- or dose-limiting pruritus through an unknown mechanism. Using unbiased high-throughput drug screens, we identified the Mas-related G protein–coupled receptor X4 (MRGPRX4), a primate-specific, sensory neuron receptor previously implicated in itch, as a potential target for phosphate-modified compounds. Using both G q -mediated calcium mobilization and G protein–independent GPCR assays, we found that phosphate-modified compounds potently activate MRGPRX4. Furthermore, a humanized mouse model expressing MRGPRX4 in sensory neurons exhibited robust phosphomonoester prodrug–evoked itch. To characterize and confirm this interaction, we further determined the structure of MRGPRX4 in complex with a phosphate-modified drug through single-particle cryo–electron microscopy (cryo-EM) and identified critical amino acid residues responsible for the binding of the phosphate group. Together, these findings explain how phosphorylated drugs can elicit treatment-limiting itch and identify MRGPRX4 as a potential therapeutic target to suppress itch and to guide future drug design.
- 8 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (746) , eadk8198
MRGPRX4 mediates phospho-drug–associated pruritus in a humanized mouse model
The phosphate modification of drugs is a common chemical strategy to increase solubility and allow for parenteral administration. Unfortunately, phosphate modifications often elicit treatment- or dose-limiting pruritus through an unknown mechanism. Using unbiased high-throughput drug screens, we identified the Mas-related G protein–coupled receptor X4 (MRGPRX4), a primate-specific, sensory neuron receptor previously implicated in itch, as a potential target for phosphate-modified compounds. Using both G q -mediated calcium mobilization and G protein–independent GPCR assays, we found that phosphate-modified compounds potently activate MRGPRX4. Furthermore, a humanized mouse model expressing MRGPRX4 in sensory neurons exhibited robust phosphomonoester prodrug–evoked itch. To characterize and confirm this interaction, we further determined the structure of MRGPRX4 in complex with a phosphate-modified drug through single-particle cryo–electron microscopy (cryo-EM) and identified critical amino acid residues responsible for the binding of the phosphate group. Together, these findings explain how phosphorylated drugs can elicit treatment-limiting itch and identify MRGPRX4 as a potential therapeutic target to suppress itch and to guide future drug design.
- Open Access
- 21 March 2024
- Published by EMBL-EBI
cryoEM structure of Gq-coupled MRGPRX4 with fospropofol bound
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.
- 21 March 2024
- Published by EMBL-EBI
Open AccesscryoEM structure of Gq-coupled MRGPRX4 with fospropofol bound
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.
- Open Access
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
A biomarker-authenticated model of schizophrenia implicating NPTX2 loss of function
CSF NPTX2 is a biomarker of schizophrenia and supports a model that integrates across genetics, pharmacology, and behavior.
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Open AccessA biomarker-authenticated model of schizophrenia implicating NPTX2 loss of function
CSF NPTX2 is a biomarker of schizophrenia and supports a model that integrates across genetics, pharmacology, and behavior.